The legitimate ones are legitimate in a specific and checkable way: a licensed clinician reviews the intake, the seller holds licensure in your state, and the pharmacy that fills the order is named. Those are the three gates, they sit above the price rather than beside it, and a different party controls each one. A seller that will not answer all three is the thing to be careful of, not telehealth as a category.
Each gate has been measured on its own, and none of the measurements is reassuring in the way a marketing page is. Which state you live in narrows what you can buy before any seller quotes you. Prescribing ran ahead of the evidence base for it, and clinicians who agree a patient qualifies are frequently unable to prescribe. A share of this market skips the gate entirely, with the drug ordered with no prescription at all.
Buying a GLP-1 through a telehealth seller changes three things at once: who decides whether a prescription is written, how quickly that decision arrives, and what the money buys. The first two are worth understanding before the third. A low monthly figure attached to a request that gets declined is not a price anyone pays, which is why every review here records a state list wherever the seller publishes one.
What the intake actually is
The published description of one direct-to-consumer model is straightforward: patients complete an online questionnaire to assess eligibility, a physician reviews it, and a prescription follows or does not[1]. In that study, a follow-up questionnaire was administered 50 days after the first prescription to record weight change, adverse events and satisfaction[1].
The person deciding is a clinician licensed in the state the patient is in, which is why a seller’s state list is a hard boundary rather than a shipping preference. A buyer outside the list is not offered a worse price; they are not offered a prescription at all. That is the gate that sits above every figure on a pricing page, and it is why a twelve-state program is not comparable on price alone with a fifty-state one.
What one platform’s own cohort looked like
A retrospective cross-sectional study used anonymized data from 966 patients who received liraglutide prescriptions through a direct-to-consumer platform between August 2022 and April 2024[1]. Seventy percent had long-standing obesity and 46.6% had a body mass index between 30 and 34.4 kg/m². Most, 88.9%, were new to GLP-1 therapy[1].
At 50 days, 85.6% reported a weight loss of more than 2 kg, with an average of 4.9 kg. Adverse events were reported by 39.8%, predominantly gastrointestinal, and 94.1% reported following the prescribed regimen. Despite the adverse events, 86.4% said they wanted to continue[1].
Where a request stalls
Three gates sit between a form and a shipment, and each is controlled by someone different. Eligibility is decided by the clinician reviewing the questionnaire. State availability is decided by licensure, which is the seller’s constraint rather than the buyer’s. Supply is decided by the pharmacy, and a model built around a specific compounded preparation has fewer alternatives than one routing to a manufacturer.
A seller that publishes its state list, its medication figure and any fee outside that figure has made all three legible before payment. A seller that publishes a membership price and calls the medication cost variable has made the first payment a condition of finding out the second. That is a materially different purchase, even where the eventual total turns out to be the same. MEDVi does this on two of its three lines.
The commercial environment is part of the access question
A commentary in Science on the consequences of mass-prescribing these drugs sets out the context every telehealth seller operates inside. The World Health Organization has published its first global guidelines recommending GLP-1s for obesity, alongside a commitment to a framework for fair access. That is unfolding amid competitive pressure from pharmaceutical companies, food companies and wellness companies marketing what the piece calls a GLP-1 lifestyle[2]. The commentary argues that this environment is itself ripe for unintended consequences working against fair access[2].
A separate report describes a virtual care model combining GLP-1 prescribing with additional clinical support, which is the shape most memberships on this desk claim to be[3]. What a membership actually buys varies enormously between sellers, and it is rarely itemized. Where it is not, the honest reading is that the fee buys access to a prescriber and nothing further has been established. The cost calculator adds a fee back to a headline figure so two sellers can be set against each other.